ASP ISOTOPES INC - Ralph Hunter joins board of directors of ASPI and board of managers of Quantum Leap Energy LLC

Ralph Hunter joins board of directors of ASPI and board of managers of Quantum Leap Energy LLC

ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")


NUCLEAR POWER INDUSTRY VETERAN RALPH HUNTER JOINS BOARD OF DIRECTORS OF
ASP ISOTOPES INC. AND BOARD OF MANAGERS OF QUANTUM LEAP ENERGY LLC


Washington, D.C., September 8, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI
("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of
technology and processes for the production of isotopes for use in multiple industries, today announced
the appointment of Ralph L. Hunter, Jr. to the board of directors of ASP Isotopes and the board of
managers of Quantum Leap Energy LLC.


Ralph L. Hunter, Jr. has over thirty years' experience in the nuclear power industry in leadership roles
spanning strategy, operations, and innovation, and he brings expertise in nuclear technology
development and commercialization, energy systems, and market development. Mr. Hunter has served
as Chair on the US Civil Nuclear Trade Advisory Committee (CINTAC) which promoted nuclear energy
exports, supported marketing U.S. civilian nuclear technologies, innovative U.S. nuclear technologies
and the capabilities of U.S. nuclear operators and suppliers. Representing Constellation Energy Corp.'s
investment in small modular nuclear reactors internationally, Mr. Hunter also served on the Board of
Rolls-Royce SMR Limited, a company that will design, manufacture, supply, assemble and commission
a total SMR power plant and is expected to be at the heart of the UK's clean energy mix by 2030.

Since June 2025, Mr. Hunter has been the Chairman and CEO of RC Nuclear Consultants, LLC, a
consulting company he established to help companies navigate the new nuclear landscape. From
February 2024 to June 2025, Mr. Hunter was President and CEO of Orion Nuclear Energy Corporation
where he led the development company in securing opportunities nationally for both small modular
reactors and micro-reactors. From 2013 to 2024, Mr. Hunter led the development of Constellation
Energy Generation's (CEG) international clean energy business in his role as President of Constellation
Generation Development, LLC (CGD), and was responsible for all of Constellation's (formerly Exelon
Generation) development activities in the nuclear sector worldwide. Mr. Hunter holds both a Bachelor
of Engineering degree in Nuclear Engineering and a Master of Engineering degree in Nuclear
Engineering from the University of Florida.

Paul Mann, Chairman and CEO of ASP Isotopes Inc. said, "We are pleased to welcome Ralph to the
board of directors of ASP Isotopes. Ralph's understanding of the US and international nuclear energy
market and complex nuclear regulatory environment will assist the Company greatly in advancing our
technologies in the United States and globally."

Mr. Hunter commented, "ASP Isotopes's plan to apply its demonstrated enrichment technologies to
uranium to produce HALEU for next-generation nuclear reactors aligns perfectly with my passion for
nuclear power and energy innovation. I'm honored to join the Board and work with the entire team to
help bring this transformative technology to the world and help deliver scalable, clean, and affordable
energy."

About ASP Isotopes Inc.

ASP Isotopes Inc. is an advanced materials company dedicated to developing technology and
processes to produce isotopes in multiple industries. The Company employs proprietary technology,
the Aerodynamic Separation Process ("ASP technology"), for the production of all isotopes. The
Company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare
and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector.
The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment
of isotopes of elements with a low atomic mass (light isotopes).

There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and
Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging
healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy
applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and
heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation,
statements relating to the plans to deploy technologies to the enrichment of uranium. Forward-looking
statements are neither historical facts nor assurances of future performance. Instead, they are based
only on our current beliefs, expectations, and assumptions regarding the future of our business, future
plans and strategies, projections, anticipated events and trends, the economy, and other future
conditions. Forward-looking statements can be identified by words such as "believes," "plans,"
"anticipates," "expects," "estimates," "projects," "will," "may," "might," and words of a similar nature.
Examples of forward-looking statements include, among others but are not limited to, statements we
make regarding expected operating results, such as future revenues and prospects from the potential
commercialization of isotopes, future performance under contracts, and our strategies for product
development, engaging with potential customers, market position, and financial results. Because
forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and
changes in circumstances that are difficult to predict, many of which are outside our control. Our actual
results, financial condition, and events may differ materially from those indicated in the forward-looking
statements based upon a number of factors. Forward-looking statements are not a guarantee of future
performance or developments. You are strongly cautioned that reliance on any forward-looking
statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any
of these forward-looking statements.

There are many important factors that could cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements, including, but not limited to: the
outcomes of various strategies and projects undertaken by the Company; the potential impact of laws
or government regulations or policies in South Africa, the United Kingdom or elsewhere; our future
capital requirements and sources and uses of cash; our ability to obtain funding for our operations and
future growth; our reliance on the efforts of third parties; our ability to complete the construction and
commissioning of our enrichment plants or to commercialize isotopes using the ASP technology or the
Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and
distribution of isotopes; the financial terms of any current and future commercial arrangements; our
ability to complete certain transactions and realize anticipated benefits from acquisitions; contracts,
dependence on our Intellectual Property (IP) rights, certain IP rights of third parties; the competitive
nature of our industry; risks related to: (i) the implementation of the scheme of arrangement for the
proposed Renergen acquisition in the anticipated timeframe or at all, (ii) the satisfaction of the scheme
conditions, (iii) the failure to obtain necessary regulatory approvals and third party consents, (iv) the
ability to realize the anticipated benefits of the proposed acquisition of Renergen, (v) the ability to
successfully integrate the businesses; (vi) disruption from the proposed acquisition of Renergen making
it more difficult to maintain business and operational relationships, (vii) the negative effects of the
consummation of the proposed acquisition of Renergen on the market price of Renergen's or ASPI's
securities, (viii) significant transaction costs and unknown liabilities, and (ix) litigation or regulatory
actions related to the proposed acquisition of Renergen; and the factors disclosed under the heading
"Risk Factors" in the company's Annual Report on Form 10-K, quarterly reports on Form 10-Q and any
other filings made with the SEC from time to time, which are available via the SEC's website at
www.sec.gov. Any forward-looking statement made by us in this press release is based only on
information currently available to us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement, whether as a result of new information,
future developments or otherwise. All forward-looking statements herein are qualified by reference to
the cautionary statements set forth herein and should not be relied upon.

Contacts

Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043


8 September 2025

Sponsor
Valeo Capital Proprietary Limited

Date: 08-09-2025 02:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.